PARP Inhibitors in Triple-Negative Breast Cancer including Those with BRCA Mutations

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Poly(ADP-ribose) polymerase (PARP) is involved in single-strand DNA break base excision repair. PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer. Breast cancers with homologous recombination deficiency or BRCAness, most commonly triple-negative breast cancers, may also benefit. Currently, PARP inhibitor use for triple-negative breast cancer with wild-type BRCA does not have definitive efficacy; however, this is an area of active research. Further clinical and translational data may identify additional patient populations that will benefit from PARP inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)67-75
Number of pages9
JournalCancer Journal (United States)
Volume27
Issue number1
DOIs
StatePublished - 2021

Keywords

  • BRCA
  • BRCAness
  • Basal-like
  • PARP inhibitor
  • breast cancer
  • homologous recombination deficiency
  • poly(ADP-ribose) polymerase
  • synthetic lethality
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'PARP Inhibitors in Triple-Negative Breast Cancer including Those with BRCA Mutations'. Together they form a unique fingerprint.

Cite this